U.S. markets closed

SciSparc Ltd. (SPRCY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
7.49+0.24 (+3.31%)
At close: 1:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close7.25
Open7.30
BidN/A x N/A
AskN/A x N/A
Day's Range7.30 - 7.50
52 Week Range3.15 - 9.50
Volume4,689
Avg. Volume14,570
Market Cap30.148M
Beta (5Y Monthly)-0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment
    PR Newswire

    SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment

    SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has signed an agreement with The Israeli Medical Center for Alzheimer's, to conduct a phase IIa clinical trial to evaluate the safety, tolerability and efficacy of SCI-110 (formerly THX-110) in patients with Alzheimer's disease and agitation using the Company's proprietary cannabinoid-based technology.

  • Market Exclusive

    GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players

    It’s been a wild ride for GW Pharmaceuticals (NASDAQ:GWPH). Founded in 1998, it took 20 years for the cannabis-centered pharma firm to achieve its first FDA approval. That was for Sativex back in 2018, a sublingual spray consisting of a mixture of different cannabinoids, used to treat spasticity from multiple sclerosis. Later that same year, […] The post GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players appeared first on Market Exclusive.

  • SciSparc Announces Rebranding and Business Updates
    PR Newswire

    SciSparc Announces Rebranding and Business Updates

    TEL AVIV, Israel, Feb. 11, 2021 SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments (formerly known as Therapix Biosciences Ltd.), today announced a series of rebranding processes.